lorigerlimab
·Code: MGD019
lorigerlimab: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| MACROGENICS INC (MGNX) | Phase 2 |
FDA Decisions
FDA_MeetingFDA placed a partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab (bispecific PD-1/CTLA-4 DART) in gynecologic cancers.(MGNX)
Frequently asked questions
Who is developing lorigerlimab?
lorigerlimab is being developed by MACROGENICS INC.
What is lorigerlimab's latest FDA decision?
The most recent tracked FDA decision for lorigerlimab is FDA_Meeting for FDA placed a partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab (bispecific PD-1/CTLA-4 DART) in gynecologic cancers., dated February 23, 2026.
Get deeper analysis on lorigerlimab
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis